nAMD: Switching Therapies - what you need to know

Slides:



Advertisements
Similar presentations
The Diabetic Retinopathy Clinical Research Network
Advertisements

The Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network
The Diabetic Retinopathy Clinical Research Network
Upfront Combination Therapy vs Step-Up Approach for PAH:
The Patient Experience With Systemic Lupus Erythematosus
The Diabetic Retinopathy Clinical Research Network
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
nAMD: Choosing the Best Treatment for your Patient
Diabetic Dyslipidemia in Practice
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC
Changing the IBD Paradigm
Clinical Trials to Real World:
Understanding Biologics
A New Era for NOACs:.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
The HCV Revolution: Are You and Your Practice Ready?
Hemophilia Updates: Incorporating New Concepts Into Practice
Optimizing Outcomes in the Management of GIST
The Diabetic Retinopathy Clinical Research Network
Optimizing Patient Outcomes in IBD
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
New Data in nAMD: What Does the Future Hold?
Chronic Idiopathic Urticaria
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Do CNV Subtypes Matter for Prognosis, Diagnosis, and Treatment?
Decision-making in the eRA of Treating to Target
CDK4/6 Inhibitors in Practice
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
Are We Closer to Personalized Medicine in MS?
nAMD: New Drugs and Practice Patterns to Improve Patient Outcomes
Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response.
Evaluating Next-Generation BTK Inhibitors
Gene Therapy: Past, Present, and Future
Personalizing Management in the Care of Patients With Advanced Sarcoma
Key Questions for nAMD Treatment Success
Developments in the Wet AMD Treatment Landscape
Intro: Biomarkers in RA
Wet AMD trials Hibba Soomro.
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
nAMD: Choosing the Best Treatment for your Patient
Guide to Atopic Dermatitis
The Rising Cost of Healthcare and Potential Impact of Biosimilars
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Critical Decision Points in Insomnia
Should We Dry the Retina Faster for Longer
Challenges in LA SCCHN.
Applying the Latest Data on Treat-and-Extend Strategies to Clinical Cases in nAMD.
The Research Question Background: Question:
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
AMD Therapy: Where Are We Now and Where Are We Going?
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
A Closer Look.
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Early Treatment of Diabetic Retinopathy
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Anemia Explored.
Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
nAMD: Why Anatomical Outcomes Matter
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Biosimilars in Immune-Related Diseases
The Power of As-Treated Analyses
Diabetic Retinopathy Clinical Research Network
What's New in NOACs in AF?.
Presentation transcript:

nAMD: Switching Therapies - what you need to know

Program Goal

Currently Available Anti-VEGF Therapies Used to Treat nAMD

12-Month Outcomes of Ranibizumab vs Aflibercept: Similar Rates of VA Improvement

Factors That Determine The Reason to Switch Therapies

EMR Study: Real World Ranibizumab Data Vs Benchmark Standards of Care

Real-World Visual Outcomes at Centers Across UK Differ From Randomized Trials

Is It Beneficial for a Patient to Switch?

Results May Vary After Switching Therapies

Two Main Reasons for Switching Therapies

Visual Function of Patient is Most Important

Can Anatomical Endpoints Guide Decisions to Switch Therapies?

Benefit of Switching: Theory

Switching From Ranibizumab to Aflibercept: Real-Life Data

Switching From Ranibizumab to Aflibercept: Real-Life Data (cont)

Significance of Switching: Study Results

The Mechanisms of Tachyphylaxis

Meta-Analysis of Studies of Patients With Treatment Resistant nAMD: Methods

Meta-Analysis Indicates High Number of Injections May Cause Resistance

Concepts of Tachyphylaxis: More Data is Needed

Concepts of Tachyphylaxis: Change in Underlying Disease

Factors That Involve Decisions to Switch Therapies

CATT Study: Results Show Discontinuous Therapy Inferior to Continuous Therapy

Real-Life Data Studies May Differ From Clinical Trial Data

Response to Anti-VEGF Therapy in nAMD

Is a Loading Phase Needed After Switching?

Patient Case Scenario

Switching Study: Ranibizumab to Aflibercept to Ranibizumab

Concluding Remarks

Abbreviations

Abbreviations (cont)